Read our COVID-19 research and news.

Webinar Technology

Characterizing genetic and epigenetic influencers of CRISPR-Cas genome-wide nuclease activity using CHANGE-seq

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Characterizing genetic and epigenetic influencers of CRISPR-Cas genome-wide nuclease activity using CHANGE-seq

11 September 2019

12:00 p.m. ET

Register to watch recording


RNA-guided CRISPR-Cas nucleases are a transformative genome-editing tool due to the simplicity with which they can be programmed to target new sites. Genome editing has the potential to fulfill medicine’s long-held aspiration to directly address the genetic causes of human diseases. An important step in translating these powerful technologies into safe, effective genomic medicines is understanding their activity and their recognition of on- and off-target sites throughout the genome. In recent years, a number of cellular and biochemical approaches have been developed to characterize the genome-wide activity of CRISPR-Cas genome editors. However, the basic principles governing their specificity remain undefined because current approaches cannot analyze the large numbers of targets required to understand these principles. In this webinar, we review considerations for evaluating the safety of genome editors for therapeutics as well as existing methods for defining the specificity of genome editors, and describe a novel method called Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by sequencing, or CHANGE-seq. Using CHANGE-seq, we can define both genetic and epigenetic factors that affect genome-wide activity in therapeutically relevant human primary T cells.

During the webinar, viewers will:

  • Learn how advances in genome-editing technology could potentially address genetic disorders
  • Increase their understanding of CRISPR-Cas genome editing activity and safety
  • Hear about CHANGE-seq, a novel high-throughput method to define the genome-wide activity of editors, and its application for understanding genetic and epigenetic factors impacting CRISPR-Cas9 activity
  • Have the opportunity to ask questions during the live event.

This Webinar will last for approximately 60 minutes.

Speaker bios

Shengdar Q. Tsai, Ph.D.

St. Jude Children's Research Hospital
Memphis, TN

Dr. Tsai completed his Bachelor’s degree at the University of Michigan, his Master’s in bioinformatics and Ph.D. in functional genomics at North Carolina State University, and a postdoctoral fellowship at Massachusetts General Hospital and Harvard Medical School in Boston. He is currently an assistant member in the Department of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee. His lab focuses on genome-editing technologies for therapeutics, with a special interest in editing human hematopoietic stem cells for the treatment of hemoglobinopathies and T cells for cancer immunotherapy. Previously, he developed methods for high-throughput genome editing using transcription activator-like effector nucleases (TALENs), and for defining and improving the genome-wide specificity of CRISPR-Cas nucleases.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here